Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections A prospective cohort study

Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections : A prospective cohort study

Copyright © 2023. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 259(2024) vom: 29. Feb., Seite 109879
1. Verfasser: Huan, Xiao (VerfasserIn)
Weitere Verfasser: Chen, Jialin, Zhong, Huahua, Xu, Yafang, Wang, Yuan, Jiang, Haoqin, Song, Jie, Yan, Chong, Xi, Jianying, Zou, Zhangyu, Zheng, Jianming, Ruan, Zhe, Tan, Song, Luo, Lijun, Luo, Sushan, Zhao, Chongbo, Pan-Yangtze River Delta Alliance for Neuromuscular Disorders (PYDAN)
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Multicenter Study Journal Article Research Support, Non-U.S. Gov't Clinical outcome Interleukin-6 Myasthenic crisis Omicron infections Peripheral immune
Beschreibung
Zusammenfassung:Copyright © 2023. Published by Elsevier Inc.
The impact of Omicron infections on the clinical outcome and immune responses of myasthenia gravis (MG) remained largely unknown. From a prospective multicenter MG cohort (n = 189) with 197 myasthenic crisis (MC), we finally included 41 independent MG patients to classify into two groups: the Omicron Group (n = 13) and the Control Group (n = 28). In this matched cohort study, all-cause mortality was 7.69% (1/13) in Omicron Group and 14.29% (4/28) in Control Group. A higher proportion of elevated serum IL-6 was identified in the Omicron Group (88.89% vs 52.38%, P = 0.049). In addition, the proportions of CD3+CD8+T in lymphocytes and Tregs in CD3+CD4+ T cells were significantly elevated in the Omicron Group (both P = 0.0101). After treatment, the Omicron Group exhibited a marked improvement in MG-ADL score (P = 0.026) and MG-QoL-15 (P = 0.0357). MCs with Omicron infections were associated with elevated serum IL-6 and CD3+CD8+T response. These patients tended to present a better therapeutic response after fast-acting therapies and anti-IL-6 treatment
Beschreibung:Date Completed 29.01.2024
Date Revised 10.04.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2023.109879